EEF1A1P25: A Potential Drug Target and Biomarker (G646612)

Target Name: EEF1A1P25

NCBI ID: G646612

EEF1A1P25

Other Name(s): Eukaryotic translation elongation factor 1 alpha 1 pseudogene 25 | eukaryotic translation elongation factor 1 alpha 1 pseudogene 25

EEF1A1P25: A Potential Drug Target and Biomarker

The eukaryotic translation elongation factor 1 alpha 1 pseudogene 25 (EEF1A1P25) is a non-coding RNA molecule that plays a critical role in the regulation of protein translation in eukaryotic cells. The foldasome protein is an important factor in protein synthesis and plays a role in gene expression and play an important role in regulation. However, abnormally expressed EEF1A1P25 may lead to protein translation disorders and malignant cell transformation. Therefore, it is of great significance to study the application of EEF1A1P25 in disease treatment and diagnosis.

First, we need to understand the structure and function of EEF1A1P25. EEF1A1P25 is a non-coding RNA molecule of 25 nucleotides in length. Its main function is to bind to the A site of eukaryotic protein ribosomes and participate in the protein translation process. By binding to the A site, EEF1A1P25 is able to recognize and bind to the mRNA AUG codon on the protein, thereby initiating the translation process of the protein. In addition, EEF1A1P25 can also bind to the promoter region on DNA, thereby participating in the regulation of gene expression.

Next, we need to understand the application of EEF1A1P25 in disease treatment and diagnosis. Since EEF1A1P25 plays an important role in protein translation, it is of great significance to study the relationship between its function and diseases. Studies have found that abnormal expression of EEF1A1P25 is closely related to the occurrence and development of a variety of diseases, including cancer, neurodegenerative diseases, immune deficiency diseases, etc. In addition, the expression level of EEF1A1P25 is also closely related to many clinical symptoms and disease prognosis, such as surgical success rate, patient survival, etc.

So, how to use EEF1A1P25 as a drug target or biomarker? First, antibodies or peptides against EEF1A1P25 can be designed, and their affinity for target cells can be determined through immunoaffinity experiments and bioinformatics analysis. This antibody or peptide can then be used to enrich EEF1A1P25 in target cells and further study its effects on target cells. In addition, EEF1A1P25 can also be used as a regulator of gene expression to regulate the expression level of EEF1A1P25 in target cells through transcription factor binding experiments and RNA interference technology, thereby studying its regulatory effect on gene expression.

Finally, we would like to emphasize that although EEF1A1P25 is a potential drug target or biomarker, further studies are needed to prove its clinical value. Currently, clinical research on EEF1A1P25 is mainly focused on cancer and neurodegenerative diseases, but its impact on other diseases still requires further study. In addition, the biological mechanism and mechanism of action of EEF1A1P25 also need to be studied in depth to better understand its application value in disease treatment and diagnosis.

In summary, EEF1A1P25 is a potential drug target or biomarker that can be used to treat a variety of diseases, such as cancer, neurodegenerative diseases, and immunodeficiency diseases. Through further research, its biological mechanism and mechanism of action can be better understood and applied in clinical practice, bringing more hope to human health.

Protein Name: Eukaryotic Translation Elongation Factor 1 Alpha 1 Pseudogene 25

The "EEF1A1P25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1A1P25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets